Evidence map›Paper›PMID 38231435›Full record

ArticleJournal of molecular neuroscience : MN2024

Uncovering the Therapeutic Potential of Phosphocreatine in Diabetic Retinopathy: Mitigating Mitochondrial Dysfunction and Apoptosis via JAK2/STAT3 Signaling Pathway.

Eskandar Qaed, Eman Alyafeai, Ahmed Al-Maamari, Mohamed Y Zaky, Marwan Almoiliqy, Bandar Al-Hamyari, Abdullah Qaid, Saeed Yafei, Waleed Aldahmash, Mueataz A Mahyoub and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Eskandar Qaed *Department of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China.
Eman Alyafeai *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Ahmed Al-Maamari *The Key Laboratory of Neural and Vascular Biology, The Key Laboratory of New Drug Pharmacology and Toxicology, Department of Pharmacology, Ministry of Education, Hebei Medical University, Shijiazhuang, China.
Mohamed Y ZakyMolecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt.
Marwan AlmoiliqyDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China.
Bandar Al-HamyariSchool of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, 730000, Lanzhou, People's Republic of China.
Abdullah QaidN.I. Pirogov Russian National Research Medical University, Moscow, Russia.
Saeed YafeiDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China.
Waleed AldahmashZoology Department, College of Science, King Saud University, P. O. Box 2455, 11451, Riyadh, Saudi Arabia.
Mueataz A MahyoubDepartment of Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Fuhan WangDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China.
Le KangDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China.
Zeyao TangDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China. zeyaotang@163.com.
Jianbin ZhangDepartment of Pharmacology, Dalian Medical University, 9 West Section, South Road of Lushun, 116044, Dalian, China. zhangjb@dmu.edu.cn.
Dalian Medical University · CNBeni-Suef University · EGFirst Affiliated Hospital of Xi'an Jiaotong University · CNHebei Medical University · CNKing Saud University · SALanzhou University · CNPirogov Russian National Research Medical University · RUWenzhou Medical University · CN

Funding

The study was supported by the Natural Science Foundation of China (no.30772601) and the University Innovation Team Project Foundation of the Education Department of Liaoning (no. LT2013019).Also,The authors extend their appreciation to the Researchers Supporting Program number (RSPD2023R1080), in King Saud University, Riyadh, Saudi Arabia. LT2013019
6 · The paper itself

Abstract

Diabetic retinopathy (DR) stands as a prevalent complication of diabetes mellitus, causing damage to the delicate retinal capillaries and potentially leading to visual impairment. While the exact underlying cause of DR remains elusive, compelling research suggests that mitochondrial energy deficiency and the excessive generation of reactive oxygen species (ROS) play pivotal roles in its pathogenesis. Recognizing that controlling hyperglycemia alone fails to reverse the defects in retinal mitochondria induced by diabetes, current strategies seek to restore mitochondrial function as a means of safeguarding against DR. To address this pressing issue, a comprehensive study was undertaken to explore the potential of phosphocreatine (PCr) in bolstering mitochondrial bioenergetics and providing protection against DR via modulation of the JAK2/STAT3 signaling pathway. Employing rat mitochondria and RGC-5 cells, the investigation meticulously assessed the impact of PCr on ROS production, mitochondrial membrane potential, as well as the expression of crucial apoptotic and JAK2/STAT3 signaling pathway proteins, utilizing cutting-edge techniques such as high-resolution respirometry and western blotting. The remarkable outcomes revealed that PCr exerts a profound protective influence against DR by enhancing mitochondrial function and alleviating diabetes-associated symptoms and biochemical markers. Notably, PCr administration resulted in an upregulation of antiapoptotic proteins, concomitant with a downregulation of proapoptotic proteins and the JAK2/STAT3 signaling pathway. These significant findings firmly establish PCr as a potential therapeutic avenue for combating diabetic retinopathy. By augmenting mitochondrial function and exerting antiapoptotic effects via the JAK2/STAT3 signaling pathway, PCr demonstrates promising efficacy both in vivo and in vitro, particularly in counteracting the oxidative stress engendered by hyperglycemia. In summary, our study sheds light on the potential of PCr as an innovative therapeutic strategy for diabetic retinopathy. By bolstering mitochondrial function and exerting protective effects via the modulation of the JAK2/STAT3 signaling pathway, PCr holds immense promise in ameliorating the impact of DR in the face of oxidative stress induced by hyperglycemia.

Indexed as

Diabetes MellitusDiabetic RetinopathyHyperglycemiaMitochondrial DiseasesAnimalsApoptosisPhosphocreatineRatsReactive Oxygen SpeciesSignal TransductionPhosphocreatineReactive Oxygen SpeciesApoptosisDiabetic retinopathy (DR)High-resolution respirometry (HRR)JAK2/STAT3Mitochondria (mt)Phosphocreatine (PCr)

Identifiers

PMID38231435
OpenAlexW4390950251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.